exocrine pancreatic insufficiency epi epidemiology forecast report

• EPI primarily results from chronic pancreatitis, pancreatic cancer, cystic fibrosis, acute pancreatitis, pancreatic or gastric surgery. Non-pancreatic causes include diabetes mellitus (Type 1 and Type 2), celiac disease, Zollinger-Ellison syndrome, inflammatory bowel disease (IBD), and others, where impaired pancreatic stimulation or glandular dysfunction contributes to enzyme deficiency.
• EPI is substantial under diagnosis, driven by nonspecific symptoms and inconsistent screening across high-risk populations, resulting in prevalence estimates that rely heavily on indirect disease modeling rather than confirmed, population-level surveillance data.
• The prevalence of EPI ranges from 50% to 75%, with the highest risk in those with Chronic Pancreatitis (CP) due to alcohol and with long disease duration.
• EPI can affect individuals of all ages, though certain populations, such as those with cystic fibrosis, chronic pancreatitis, and other pancreatic diseases, are more prone to this condition. It’s estimated that a significant number of individuals with chronic pancreatitis and cystic fibrosis suffer from EPI.

Exocrine Pancreatic Insufficiency (EPI) Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of EPI: ~ USD XX million
• 2036 Projected Diagnosed Prevalent Cases of EPI: ~ USD XX million
• EPI Growth Rate (2026–2036): ~XX % CAGR

DelveInsight's ‘Exocrine Pancreatic Insufficiency (EPI) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Exocrine Pancreatic Insufficiency (EPI), historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Exocrine Pancreatic Insufficiency (EPI) Understanding and Diagnostic Algorithm

Exocrine Pancreatic Insufficiency (EPI) Overview and Diagnosis

EPI is a digestive disorder caused by inadequate secretion of pancreatic enzymes required for fat, protein, and carbohydrate digestion. It commonly occurs secondary to pancreatic and non-pancreatic diseases and leads to clinically significant malnutrition and gastrointestinal complications.It commonly occurs as a consequence of chronic pancreatitis, cystic fibrosis, pancreatic cancer, pancreatic surgery, or other gastrointestinal disorders that impair pancreatic function. Patients with EPI typically present with symptoms such as steatorrhea, diarrhea, abdominal discomfort, bloating, unintended weight loss, malnutrition, and deficiencies of fat-soluble vitamins due to impaired nutrient absorption. The condition can significantly affect quality of life and nutritional status if left untreated. Diagnosis involves a combination of clinical evaluation, assessment of symptoms, nutritional status, and laboratory investigations. Fecal elastase-1 testing is widely used as a noninvasive diagnostic tool to evaluate pancreatic enzyme secretion, while additional tests such as direct pancreatic function testing, fecal fat quantification, imaging studies, and nutritional assessments may provide supportive evidence. Management primarily focuses on PERT, dietary modifications, and correction of nutritional deficiencies to improve digestion, symptom control, and overall patient outcomes.

Further details are provided in the report.

Exocrine Pancreatic Insufficiency (EPI) Epidemiology

Key Findings from Exocrine Pancreatic Insufficiency (EPI) Epidemiological Analysis and Forecast 

• Autoimmune pancreatitis is often associated with EPI, it is prevalent in cystic fibrosis, affecting approximately 85% of individuals from birth or infancy. In pancreatic ductal adenocarcinoma, the rates of EPI range from 50% to 92% in unresectable cases.
• The prevalence of EPI in newly diagnosed Crohn’s Disease (CD) patients ranges from 10.5% to 46.5%, with a pooled prevalence of 26.2% (95% CI 8.43–43.92%). In CD patients on a gluten-free diet (GFD), the rate of EPI ranges from 1.9% to 18.2%.
• As per DelveInsight estimates, in the United States, major causative indication of EPI were Type II diabetes, followed by Celiac disease, among the other causative diseases like Mild Acute Pancreatitis, Moderate to Severe Acute Pancreatitis Chronic Pancreatitis, Cystic Fibrosis, Crohn's Disease, and others. 
• Among the EU4 and the UK, Germany accounted for highest prevalence cases of EPI by various causative indication and least cases were observed in Spain.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of EPI, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

• EPI Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of EPI? What will be the growth opportunities across the 7MM concerning the patient population with EPI?
• What is the historical and forecasted EPI patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.